CJC-1295 No DAC + Ipamorelin
This vial pre-blends two growth-hormone secretagogues that are almost always studied together: CJC-1295 without DAC, a short-acting analog of growth-hormone-releasing hormone (GHRH), and Ipamorelin, a selective ghrelin-receptor agonist. Each 10 mg vial carries 5 mg of each peptide, so one reconstitution and one injection cover both.
Mechanism
- Two receptors, one pulse. CJC-1295 (no DAC) binds pituitary GHRH receptors; Ipamorelin binds the ghrelin receptor (GHS-R1a). Acting on separate receptors, the pair is studied for a larger GH pulse than either produces alone, while keeping release pulsatile rather than continuous.
- Short-acting by design. Without the DAC modification, CJC-1295 clears in minutes rather than days, which matches Ipamorelin's short half-life — the reason the two are blended rather than dosed on separate schedules.
- Selectivity. Ipamorelin is characterized by minimal effect on cortisol or prolactin at commonly studied doses, compared with earlier GHRPs.
Common research protocols
Dosing information below reflects published research and community protocol literature. It is not medical advice and is not a treatment plan.
- Route. Subcutaneous injection, once daily, most often at bedtime on an empty stomach.
- One progressive schedule, not separate tiers. Protocols start low — about 100 mcg of each peptide (200 mcg of blend) per injection — and step up slowly over several weeks. Sources that go higher top out around 200–300 mcg of each. This site lists the entry dose; there are no separate aggression levels for this blend.
- Cycle. Typically 8–12 weeks, followed by a break of at least 4 weeks.
- Vial check. Even the top of the published range (300 mcg of each, 600 mcg of blend) is about 6% of a 10 mg vial per injection.
- Chart row. Vial, water, concentration and syringe units are on the dosage chart.
Drawn from community and aggregator protocol literature, deliberately biased toward the low end. The combination has not been tested in a published human randomized trial.
Evidence at a glance
- Regulatory status. Neither peptide is FDA-approved. Both are investigational growth-hormone secretagogues.
- Human data. Each component has short-term human data for GH release on its own (Ipamorelin in 1990s trials; CJC-1295 mostly as the long-acting DAC form). Data on the two together comes mainly from research and community protocols, not controlled trials.
- What we do not know. Long-term effects of repeated daily dosing, and how the combined pulse compares with each peptide alone in humans.
Reconstitution & handling
Ships as freeze-dried powder. A common ratio is 2 mL of bacteriostatic water, giving 5 mg/mL of blend (2.5 mg/mL of each), so the 200 mcg entry dose is 4 units on a U-100 syringe. Refrigerate once reconstituted. The reconstitution calculator opens with those numbers loaded. General syringe guidance is on the How We Work page.
Primary-literature list for this guide available on request via contact.